



Resource impact template

Resource impact

Published: 28 August 2025

www.nice.org.uk

NICE has produced a [resource impact template](#) that incorporates the following technology appraisals for previously treated moderately to severely active Crohn's disease:

- [guselkumab for previously treated moderately to severely active Crohn's disease](#) (2025) NICE technology appraisal guidance 1095
- [mirikizumab for previously treated moderately to severely active Crohn's disease](#) (2025) NICE technology appraisal guidance 1080
- [upadacitinib for previously treated moderately to severely active Crohn's disease](#) (2023) NICE technology appraisal guidance 905
- [risankizumab for previously treated moderately to severely active Crohn's disease](#) (2023) NICE technology appraisal guidance 888
- [ustekinumab for moderately to severely active Crohn's disease after previous treatment](#) (2017) NICE technology appraisal guidance 456.